Sign up to save your podcasts
Or
Share CD19-Targeting in Relapsed/Refractory DLBCL: Optimizing the Use of Noncellular Therapies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CD19-Targeting in Relapsed/Refractory DLBCL: Optimizing the Use of Noncellular Therapies
Did you know that noncellular CD19-targeted therapies represent a new therapeutic option in both transplant eligible and ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
Credit available for this activity expires: 10/18/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/997427?ecd=bdc_podcast_libsyn_mscpedu
View all episodes
By Medscape Podcasts
4
77 ratings
Did you know that noncellular CD19-targeted therapies represent a new therapeutic option in both transplant eligible and ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
Credit available for this activity expires: 10/18/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/997427?ecd=bdc_podcast_libsyn_mscpedu
More shows like Keeping Current
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
500 Listeners
Diabetes Core Update
101 Listeners
This Week in Cardiology
883 Listeners
The Bob Harrington Show
13 Listeners
One-on-One with Eric Topol
17 Listeners
Mayo Clinic Talks
289 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,149 Listeners
Annals On Call Podcast
190 Listeners
JAMA Medical News
88 Listeners
The Clinical Problem Solvers
514 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
369 Listeners
Medicine and the Machine
61 Listeners
Keeping Current CME
26 Listeners
Cardionerds: A Cardiology Podcast
432 Listeners
The Curious Clinicians
372 Listeners